



ASX release

2 December 2010

Rights Issue Successfully Completed

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced the results of its 1 for 6 non-renounceable rights offer announced on 20 October 2010.

AtCor received applications for approximately \$953,000 comprising \$745,000 in entitlement acceptances and \$208,000 as applications for additional shares. This represents 71% of available shares taken up. All valid applicants will receive their full entitlement and any additional shares applied for through the offer. This will result in 13,617,995 new shares being issued. As a fully underwritten offer, the shortfall of 5,538,949 shares will be issued to clients of the Underwriter, Taylor Collison Limited as per the terms of the underwriting agreement.

In accordance with the timetable for the rights offer, it is expected that:

- Allotment and issue of shares under the offer will occur on 2 December 2010;
- Normal trading of the new shares will occur on 3 December 2010; and
- Holding statements for the new shares will be dispatched by 6 December 2010.

Duncan Ross, CEO of AtCor said “The Board and I are pleased with the level of participation in the rights offer, particularly as a number of overseas shareholders were unable to participate. This, combined with the share placement in October, provides us with the funds to develop the business through to self-sustainability. The cash raised will be directed towards funding working capital needs associated with a change in the nature of pharmaceutical receivables (leasing model versus up front capital), accelerating our product development program, and supporting reimbursement activities in the USA.”

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au